Two new studies that showed the updated COVID-19 boosters provoked an immune response similar to the one triggered by the old boosters will not have an effect on the U.S. Food and Drug Administration’s emergency use authorizations, a top regulator says.
Dr. Peter Marks, head of the FDA’s Center for Biologics Evaluation and Research, told The Epoch Times via email that the studies were based on “small numbers of individuals” and that data from larger studies are expected to be available soon.